Misonix, Inc., an ultrasonic medical devices company, announced that it had received a letter from the Securities and Exchange Commission informing the company that the SEC staff was closing its investigation with a recommendation of no enforcement action by the SEC. The company had previously reported that it had made a voluntarily disclosure to the SEC relating to possible FCPA issues caused by the business practices of the company’s distributor in China.
June 20, 2019
New York medical technology company receives declination letter from SEC in suspected foreign bribery case
Related by Topic
New Post
DOJ Issues New FCPA Enforcement Guidelines Focused on U.S. Economic and National Security Interests
June 12, 2025
Insight
New Post
FCA publishes new Enforcement Guide and reveals new approach to enforcement investigations
June 5, 2025
News Alert